Ocugen Patient Engagement

Ocugen Patient Engagement A fully integrated, patient-centric biotech company focused on vaccines and gene therapies.

06/17/2026

“I have more adaptation to light and darkness.” – Nancy

After living with retinitis pigmentosa for 31 years, Nancy shares her story and why she remains hopeful for the future after participating in Ocugen’s OCU400 clinical trial.

Listen to Nancy's story and discover the impact vision can have on everyday life.

To learn more about Ocugen’s novel modifier gene therapy candidates, visit: https://bit.ly/4bjhov5

What makes OCU400 different?Retinitis pigmentosa (RP) can be caused by more than 150 genetic mutations. OCU400 is design...
06/09/2026

What makes OCU400 different?

Retinitis pigmentosa (RP) can be caused by more than 150 genetic mutations. OCU400 is designed to address multiple RP mutations through a potential one-time therapy.

Follow us as we advance OCU400 toward a planned BLA submission this year.

Promising early safety and efficacy results continue to reinforce the potential of OCU410ST for Stargardt disease. At 12...
06/05/2026

Promising early safety and efficacy results continue to reinforce the potential of OCU410ST for Stargardt disease.

At 12 months, treated eyes demonstrated a 54% reduction in atrophic lesion growth, while 100% of evaluable treated eyes showed stabilization or improvement in visual function and achieved a +6 letter gain in visual acuity.

Hear directly from an OCU410ST clinical trial participant and learn more about their experience: https://bit.ly/3Q9CBiI

What is Retinitis Pigmentosa (RP)?RP is a group of rare, inherited eye diseases that cause progressive vision loss over ...
06/04/2026

What is Retinitis Pigmentosa (RP)?

RP is a group of rare, inherited eye diseases that cause progressive vision loss over time. People with RP may have trouble seeing at night and can gradually lose their side vision. More than 150 genetic mutations can cause RP, making it difficult to treat.

OCU400, Ocugen's lead novel modifier gene therapy, is designed to address over 98% mutations associated with RP with a single, one-time treatment. By supporting retinal cells, OCU400 has the potential to preserve and restore vision for people living with RP, for whom no treatment currently exists.

Awareness starts with a conversation. Share this post to help educate others about RP.

What is Stargardt disease?Stargardt disease is a rare inherited eye disease that slowly takes away central vision, makin...
05/18/2026

What is Stargardt disease?

Stargardt disease is a rare inherited eye disease that slowly takes away central vision, making it harder to read, recognize faces, and see the world clearly over time. It affects the retina, the light-sensitive tissue in the back of the eye that helps us process what we see.

Ocugen is studying a potential gene therapy, OCU410ST, with the hope of slowing the progression of disease and helping protect vision for the future. Every step forward brings hope to individuals and families affected by inherited retinal diseases.

Like and share this post to help more people learn about Stargardt disease and inherited retinal diseases.

During , Ocugen shared a poster presentation on reducing variability in quantitative autofluorescence measurements thro...
05/11/2026

During , Ocugen shared a poster presentation on reducing variability in quantitative autofluorescence measurements through automation for & . Proud to support innovation advancing research for blindness diseases.

ARVO

What is the Ellipsoid Zone (EZ)? EZ is a structural biomarker for photoceptor integrity which correlates to visual funct...
05/01/2026

What is the Ellipsoid Zone (EZ)? EZ is a structural biomarker for photoceptor integrity which correlates to visual function.

If you found this helpful, share it with someone who should know more about EZ.

04/22/2026

Susan, an OCU410ST clinical trial participant, shares her experience after treatment for Stargardt disease, reporting stabilization in the treated eye while the untreated eye continued to decline.

Now being studied in the Phase 2/3 GARDian3 pivotal confirmatory trial, OCU410ST is designed to slow or potentially even reverse disease progression.

Turn on notifications for Ocugen by clicking the "Follow" button in the top right corner of our Facebook to stay up to date on patient journeys and more Ocugen news.

Address

11 Great Valley Parkway
Malvern, PA
19355

Website

Alerts

Be the first to know and let us send you an email when Ocugen Patient Engagement posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Ocugen Patient Engagement:

Shortcuts

Share

Category